AI Summary & Key Takeaways
AI InsightConclusion: Iron sucrose was safe and effective in treatment of patients with iron deficiency anemia who require blood transfusion.
📌 3 Key Takeaways
Abstract
Objective: To evaluate effectiveness of intravenous iron sucrose in the treatment of iron deficiency anemia. Methods: A prospective study was done in 97 patients with iron deficiency anemia (hemoglobin < 10 g/dl). The patients were anemic due to long period of vaginal bleeding, before or after abdominal surgery (hysterectomy, myomectomy, and laparotomy). Cases were treated with iron sucrose instead of blood transfusion. Efficacy of treatment was assessed by determining the change in hemoglobin, hematocrit, and platelet levels after one month. All patients were monitored for adverse effects. Results: The mean age, gravida, parity of patients were 41.8±7.4 years, 3.6±2.5,2.3±1.5, respectively. Fifty-one (52.6%) patients had anemia after long vaginal bleeding period and 46 (47.4%) after abdominal surgery. Hemoglobin, hematocrit, platelet levels of cases were 7.8±0.6 g/dl, 27.3±2.2, 297896±95603.5, respectively. The mean of iron sucrose dose given during the treatment was 290±130 mg (range 200-900mg).After one month of therapy hemoglobin, hematocrit, and platelet levels were 9.9±0.9 g/dl, 33.7±2.6, 414838±470905, respectively. Significant increase in parameters was found at the end of therapy (p< 0.0001). Five patients (5.2%) experienced fever, tremble during infusion of iron sucrose. No serious adverse effects were seen. Conclusion: Iron sucrose was safe and effective in treatment of patients with iron deficiency anemia who require blood transfusion.
Özet
Amaç: Demir eksikliği anemisinde intravenöz demir sukroz tedavisinin etkinliğini araştırmak Materyal ve Method: Uzun süren vajnal kanamaya bağlı, abdominal cerrahi (histerektomi, myomektomi ve laparotomi) öncesi veya sonrasında demir eksikliği anemisi (hemoglobin < 10g/dl) gelişen 97 olgu prospekif çalişmaya alındı. Olgular demir sukroz ile tedavi edildi. Tedavinin etkinliği, bir ay sonra hemoglobin, hematokrit ve trombosit seviyeleri ölçülerek değerlendirildi. Olgular yan etkiler açısından gözlendi. Bulgular: Olguların ortalama yaşı 41.8±7.4 yıl, gravidası 3.6±2.5, paritesi 2.3±1.5 idi. Hastaların 5 l'inde (%52.6) uzun süren vajnal kanama, 46'sında (%47.4) abdominal cerrahi sonrası anemi tespit edildi. Anemi tedavisi öncesi ortalama hemoglobin düzeyi 7.8±0.6 g/dl, hematokrit 27.3±2.2, trombosit 297896±95603.5/mm3 idi. Tedavide ortalama 290±130 mg ( 200-900mg) demir sukroz infüzyonu yapıldı. Tedaviden bir ay sonraki hemoglobin, hematokrit, trombosit düzeyleri sırasıyla 9.9±0.9 g/dl, 33.7±2.6, 414838±470905/mm' olarak ölçüldü. Tedavi sonunda tüm parametrelerde belirgin artış tespit edildi (p